Molecular and Cellular Biology, December 1998, p. 7444-7454, Vol. 18, No. 12
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
University of Southern California/Norris Cancer Center and Department of Biochemistry and Molecular Biology, University of Southern California School of Medicine, Los Angeles, California 90033
Received 13 May 1998/Returned for modification 15 June 1998/Accepted 20 August 1998
| |
ABSTRACT |
|---|
|
|
|---|
The Ras-related GTPases are small, 20- to 25-kDa proteins which
cycle between an inactive GDP-bound form and an active GTP-bound state.
The Ras superfamily includes the Ras, Rho, Ran, Arf, and Rab/YPT1
families, each of which controls distinct cellular functions. The
crystal structures of Ras, Rac, Arf, and Ran reveal a nearly superimposible structure surrounding the GTP-binding pocket, and it is
generally presumed that the Rab/YPT1 family shares this core structure.
The Ras, Rac, Ran, Arf, and Rab/YPT1 families are activated by
interaction with family-specific guanine nucleotide exchange factors
(GEFs). The structural determinants of GTPases required for interaction
with family-specific GEFs have begun to emerge. We sought to determine
the sites on YPT1 which interact with GEFs. We found that mutations of
YPT1 at position 42, 43, or 49 (effector loop; switch I), position 69, 71, 73, or 75 (switch II), and position 107, 109, or 115 (alpha-helix
3-loop 7 [
3-L7]) are intragenic suppressors of dominant
interfering YPT1 mutant N22 (YPT1-N22), suggesting these mutations
prevent YPT1-N22 from binding to and sequestering an endogenous GEF.
Mutations at these positions prevent interaction with the DSS4 GEF in
vitro. Mutations in the switch II and
3-L7 regions do not prevent
downstream signaling in yeast when combined with a GTPase-defective
(activating) mutation. Together, these results show that the YPT1
GTPase interacts with GEFs in a manner reminiscent of that for Ras and
Arf in that these GTPases use divergent sequences corresponding to the
switch I and II regions and
3-L7 of Ras to interact with
family-specific GEFs. This finding suggests that GTPases of the Ras
superfamily each may share common features of GEF-mediated guanine
nucleotide exchange even though the GEFs for each of the Ras
subfamilies appear evolutionarily unrelated.
| |
INTRODUCTION |
|---|
|
|
|---|
The small GTPases of the Ras superfamily are involved in regulating many intracellular processes, including cell growth and division, cell morphology and movement, vesicular transport, and nuclear events (4, 40, 41). These proteins, which act as molecular switches to control various functions in the cell, are in the active, or "on," state when bound to GTP and the inactive, or "off," state when bound to GDP. The immediate control of these GTPase-mediated events resides in the proteins which regulate their GTP- or GDP-binding status. Two classes of regulatory proteins have been identified: the guanine nucleotide exchange factors (GEFs), whose physiological function is to convert GTPases from a GDP-bound state to a GTP-bound state, and the GTPase-activating proteins (GAPs), which turn off the GTPases by activating an intrinsic GTPase activity (3, 42, 44). The GEFs stimulate guanine nucleotide release to yield a GEF-apo-GTPase reaction intermediate and, in part because the GTP concentration in cells is higher than that of GDP, the formation of active GTP-bound GTPase is favored (61).
Most of our understanding of the physical interaction of these regulatory molecules with the small GTPases is based on studies of the Ras protein (3, 42-44). For example, it is known that Ras GAPs bind to the effector loop of Ras (3, 42-44). The Ras effector loop, comprising residues 30 to 45, also interacts with the known downstream targets of Ras (42-44, 79).
Numerous groups have contributed to the effort to identify Ras residues
which are involved in interactions with GEFs. Residues 62 to 75 in the
switch II region of H-ras were found to be involved, as were residues
103 and 105 in the alpha-helix 3-loop 7 (
3-L7) region (16, 38,
49, 57, 59, 60, 68, 69, 73). The effector loop (switch I region)
of Ras was also implicated in direct interactions with GEFs (5,
38, 47, 79). The switch I, switch II, and
3-L7 regions of
H-ras are found adjacent to each other on the surface of the molecule,
as would be expected for a surface domain involved in GEF binding (see
Fig. 7) (36). The recently described crystal structure of
H-ras complexed with Sos demonstrates that each of these three regions
is indeed at the interface of the Ras-Sos complex (5).
Ras GEFs exhibit a modest preference for binding GDP-bound forms of Ras, whereas Ras GAPs preferentially bind GTP-bound forms (28, 37, 45, 49, 74). Thus, the GEFs and GAPs which affect the nucleotide-binding status of Ras preferentially bind their respective substrates rather than their products. The high affinities for substrates likely reflect structural differences between the two nucleotide-bound forms of Ras. Significantly, the switch I and switch II regions of H-ras, known to have altered structures when bound to either GDP or GTP, fall within the regions implicated in interactions with GEFs and GAPs (66).
Recently, the crystal structure of the Sec7 domain of human Arno, a GEF
for the Arf GTPase, and an analysis of the interaction sites of these
two proteins have been reported (48). The analysis revealed
that Arf interacts with its exchange factor in a manner reminiscent of
the Ras interaction with its GEFs. Arf appears to use three
noncontiguous segments of its polypeptide to interact with Sec7.
Importantly, these three regions of the Arf protein are analogous to
those used by Ras to interact with its GEFs. The switch I region
(effector loop) and switch II region of Arf and Ras interact with their
GEFs (5, 38, 47, 48, 79). Also, Ras residues 103 to 105 in
the
3-L7 region and the corresponding residues of Arf (residues 113 to 115) appear to bind GEFs (5, 24, 48, 68, 69). While the
GEF-binding sequences of Arf and Ras are at analogous positions in the
GTPases, GEF-binding sequences of Ras do not show homology with the Arf
sequences. The finding that these two distantly related GTPases use
analogous regions to interact with their GEFs raises several questions
relating to other subclasses of GTPases. For example, do the Rho and
Rab/YPT1 families of GTPases interact with their GEFs by using domains analogous to those used by Ras and Arf? Do the different families of
GEF use a similar mechanism for catalyzing guanine nucleotide exchange
on small GTPases?
We undertook the present study to ask whether other small GTPases use the regions corresponding to the GEF-binding domain of H-ras to interact with their cognate GEFs. For this study, we chose the yeast YPT1 protein, which is a member of the Rab family of small GTPases (22, 29, 70). This family of proteins is involved in regulating vesicular transport (54, 55). Previously we used a yeast genetic screen to identify Ras residues which were involved in binding to Ras GEFs (49). This screen uses both a dominant interfering mutant and a constitutively active mutant of Ras. Here we created analogous YPT1 mutants and demonstrated that they could be used in a similar genetic screen. We demonstrated that the mechanism of dominant interference of YPT1 mutant N22 (YPT1-N22) is sequestration of an endogenous essential GEF for YPT1 such that a lethal phenotype occurs because endogenous YPT1 cannot be activated. Using both site-directed and random mutagenesis procedures, we identified a series of intragenic suppressors of YPT1-N22, among which we predicted would be mutants which fail to sequester essential GEFs for YPT1 due to the loss of a complete GEF-binding domain.
Among the intragenic suppressor mutations, we identified 10 residues,
at positions 42, 43, 49, 69, 71, 73, 75, 107, 109, and 115, which were
involved in in vitro binding to DSS4, a GEF which can stimulate
nucleotide exchange on YPT1 in vitro (10, 50). The positions
of these residues correspond to the switch I, switch II, and
3-L7
regions of Ras, the same regions found to be important for Ras
interaction with GEFs.
Our findings suggest that the interaction of Ras with its specific GEFs may prove to be a useful model for analyzing the structural basis underlying the interaction of other small GTPases with their cognate GEFs. Further, our findings, together with an analysis of the interactions of Ras and Arf GTPases with their GEFs, indicate that small GTPases of the Ras superfamily use similar regions for interactions with GEFs, suggesting a similar catalytic mechanism of guanine nucleotide exchange for all small GTPases.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Molecular cloning of YPT1 and DSS4. Wild-type YPT1 and the mutants YPT1-V17 and YPT1-N22 were amplified by PCR and subcloned into the yeast expression vector pYES2 (Invitrogen) for yeast genetic experiments and into the Escherichia coli expression vector pRSETA (Invitrogen) or pGEX-2T (Pharmacia) for the generation of histidine (His)-tagged fusion proteins or glutathione S-transferase (GST) fusion proteins, respectively. Plasmids harboring the original wild-type YPT1 and YPT1-V17 alleles were obtained from Sara Jones and Nava Segev. YPT1-N22 was generated by site-directed mutagenesis of wild-type YPT1 DNA by PCR as described below. pYES2 contains the yeast 2µm origin of replication, the GAL1 promoter, and URA3 as a selectable marker. Yeast genomic DSS4 DNA was amplified by PCR, subcloned into pBluescript (Stratagene), and then further subcloned into the yeast expression vector pAD4 in the correct (DSS4) and incorrect (rev-DSS4) orientations and into the E. coli expression vector pMAL (New England Biolabs) for production of the maltose-binding protein (MBP) fusion MBP-DSS4. pAD4 contains the yeast 2µm origin of replication, the alcohol dehydrogenase (ADH) promoter, and LEU2 as a selectable marker. All constructs made by PCR were verified by DNA sequence analysis.
Random hydroxylamine mutagenesis of YPT1-N22.
Hydroxlamine
mutagenesis was performed as described before (49). Briefly,
10 µg of pYES2 YPT1-N22 DNA in 400 µl of 0.25 M
K2PO4 (pH 6.0)-5 mM EDTA was mixed with 800 µl of freshly made 1.0 M hydroxlamine-HCl in 0.4 N NaOH and heated
for 1 h at 75°C. After dialysis overnight at 4°C against three
changes of 2 liters of 10 mM Tris-HCl (pH 8.0)-1 mM EDTA, the DNA was
precipitated with 2.5 volumes of 100% alcohol and washed in 70%
alcohol. The precipitated DNA was recovered by centrifugation, dried
under vacuum, dissolved in 20 µl of 10 mM Tris-HCl (pH 8.0)-0.1 mM
EDTA, and then used to generate an amplified library of mutagenized plasmid DNA in E. coli DH5
.
Site-directed mutagenesis of YPT1. Second-site mutations in YPT1-N22 were generated by PCR with oligonucleotide primers containing base substitutions as described before (49, 56). Overlapping PCR fragments each containing the new substitution were generated and then combined in a second round of PCR with oligonucleotide primers flanking the intact coding sequence and encoding HindIII and BamHI restriction sites at the 5' and 3' ends of YPT1, respectively. The resulting fragments containing both N22 and the new YPT1 mutations were subcloned into HindIII-BamHI-digested pYES2. New mutations were confirmed by DNA sequence analysis (K68, C71, T73, L75, C79, K105, A107, D109, I111, A113, and R115) and then transferred from the pYES2 YPT1-N22 plasmids into pYES2 YPT1 (wild type) or pYES2 YPT1-V17 via a MunI-SpeI restriction fragment (codons 40 to 151) and into pRSETA YPT1 (wild type) via a MunI-XhoI restriction fragment (codons 40 to 206). pYES2 constructs were used for yeast genetic experiments, and pRSETA constructs were used to produce His-tagged fusion proteins in E. coli BL21(DE3).
Suppression of the dominant interfering lethal phenotype of
YPT1-N22 by overexpression of DSS4.
Lithium acetate-competent
cells of yeast strain W303-1B (MAT
ade2 can1 his3 leu2
trp1 ura3) (from Doug Johnson) (81) were transformed
simultaneously with pYES2 plasmid DNA carrying YPT1-N22 and pAD4
plasmid DNA carrying DSS4 in either the correct (DSS4) or the incorrect
(rev-DSS4) orientation or the empty pAD4 plasmid. The transformed cells
were spread on synthetic complete (SC) medium without uracil and
leucine (SC
Ura
Leu medium) but containing 2%
glucose and incubated for 3 to 4 days at 37°C. Two to four
independent colonies from each transformation were patched on
SC
Ura
Leu medium containing either 2% glucose or 2%
galactose and incubated for 3 to 4 days at 37°C. Growth of
transformants on galactose medium at 37°C was an indication that
overexpression of DSS4 had suppressed the dominant interfering lethal
phenotype of YPT1-N22.
Selection of intragenic suppressors of YPT1-N22.
Lithium
acetate-competent cells of yeast strain W303-1B were transformed with
hydroxylamine-mutagenized pYES2 YPT1-N22 plasmid DNA, spread on
SC
Ura medium containing 2% glucose, and incubated for 3 days at 28°C. About 10,000 transformants were replica plated onto
SC
Ura medium containing either 2% glucose or 2%
galactose and incubated for 3 to 4 days at 37°C. Individual
transformants picked from the galactose medium were streaked on the
same medium and incubated for 3 days at 37°C. Plasmid DNA recovered
from these transformants was amplified in E. coli DH5
and
then used to transform yeast strain W303-1B. In each case, the plasmid
DNA conferred the ability to suppress the lethal phenotype of the
dominant interfering YPT1-N22 mutation. New YPT1 mutations were
identified by DNA sequence analysis (K42, E42, M43, I49, C69, R83, N89,
I91, L95, and I101) and then transferred into pYES2 YPT1 (wild type),
pYES2 YPT1-V17, or pGEX-2T YPT1 (wild type) via a
MunI-SpeI restriction fragment (codons 40 to 151)
and into pRSETA YPT1 (wild type) via a MunI-XhoI
restriction fragment (codons 40 to 206).
Suppression of the dominant interfering lethal phenotype of
YPT1-N22 by site-directed mutations.
Lithium
acetate-competent cells of yeast strain W303-1B were transformed
with pYES2 YPT1 plasmids containing the N22 mutation and one of the
site-directed mutations described above (K68, C71, T73, L75, C79, K105,
A107, D109, I111, A113, and R115). The cells were then spread on
SC
Ura medium containing 2% glucose and incubated for 3 to 4 days at 28°C. Three independent colonies from each
transformation were patched on SC
Ura medium containing
2% glucose or 2% galactose and incubated for 3 to 4 days at 37°C.
Growth of transformants on galactose medium at 37°C was an indication
that the site-directed mutation had suppressed the dominant interfering
lethal phenotype of the YPT1-N22 mutation.
Suppression of the loss of YPT1 function in temperature-sensitive
yeast strains.
Lithium acetate-competent cells of the
temperature-sensitive yeast strain NSY161 (MAT
his4-539
ura3-52 ypt1-A136D) (from Sara Jones and Nava Segev)
(32) were transformed with the pYES2 empty vector or pYES2
plasmid DNA carrying YPT1 (wild type) and a YPT1 mutation (C69, C71,
T73, L75, A107, D109, or R115) or pYES2 plasmid DNA carrying YPT1-V17
and a YPT1 mutation (K68, C69, C71, T73, L75, C79, R83, N89, I91, L95,
I101, K105, A107, D109, I111, A113, or R115). The cells were then
spread on SC
Ura medium containing 2% glucose and
incubated for 3 to 4 days at 28°C. Two independent colonies from each
transformation were patched on SC
Ura medium containing
2% glucose (YPT1-V17 or wild type YPT1 with one of the mutations), 2%
galactose (YPT1-V17 with one of the mutations), or 1.99% glycerol plus
0.01% galactose (wild-type YPT1 with one of the mutations) and
incubated for 3 to 4 days at 37°C. Growth of transformants on
galactose medium at 37°C was an indication that the pYES2 YPT1 mutant
plasmid had suppressed the loss of YPT1 function in yeast.
Preparation of His-tagged YPT1, His-tagged H-ras, GST-YPT1, and
MBP-DSS4 proteins.
Wild-type H-ras, wild-type YPT1, and mutant
YPT1 cDNAs were cloned into the bacterial expression vector pRSETA and
expressed in E. coli BL21(DE3) or cloned into pGEX-2T and
expressed in E. coli DH5
. Induction and purification of
the His-tagged fusion and GST fusion proteins were performed as
described previously (56). Wild-type DSS4 cDNA cloned into
the bacterial expression vector pMAL was expressed in E. coli DH5
. Induction and purification of the MBP-DSS4 fusion
protein were performed as suggested by the manufacturer. The final
concentration and purity of expressed proteins were determined by
sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE)
with Coomassie blue staining.
In vitro binding assay for YPT1 (His tagged or GST fusion) and MBP-DSS4 proteins. MBP-DSS4 fusion protein (20 pmol) bound to amylose resin in 25 µl of binding buffer (buffer G, which consisted of 50 mM Tris-HCl [pH 7.5], 5 mM MgCl2, 20 mM KCl, and 1 mM dithiothreitol [DTT] containing 500 µg of bovine serum albumin [BSA] per ml and 1 mM ZnCl2) was added to 300 µl of binding buffer containing 100 pmol of His-tagged YPT1, His-tagged Ras, GST-YPT1, or GST proteins in the nucleotide-free state or bound to GDP or GTP. The mixture was rotated for 90 min at room temperature. The amylose resin was pelleted by brief centrifugation and washed five times in 1 ml of buffer G containing 1% Triton X-100 and once in 1 ml of buffer G. Resin-bound proteins were dissolved in 15 µl of sample loading buffer, heated for 3 min at 95°C, separated by SDS-PAGE and analyzed by Western blotting by use of anti-His tag antibodies (Qiagen) with goat anti-mouse immunoglobulin G or anti-GST antibodies (Santa Cruz) with goat anti-rabbit immunoglobulin G and an Immun-Star kit as described by the manufacturer (Bio-Rad).
Intrinsic GTPase activity.
The rate of intrinsic GTP
hydrolysis of YPT1 (wild type) or YPT1-V17 protein was determined by a
modification of a method described previously (71).
His-tagged YPT1 (wild type) or YPT1-V17 protein (50 pmol) was incubated
in a 50-µl reaction mixture containing 50 nM
[
-32P]GTP (6,000 Ci/mmol), 20 mM Tris (pH 8.0), 2 mM
DTT, and 1 mM EDTA for 5 min at 25°C to bind GTP. Four volumes of
buffer A (20 mM Tris [pH 8.0], 100 mM NaCl, 5 mM MgCl2, 2 mM DTT, 500 µg of BSA per ml) preheated to 35°C were added to the
reaction mixture, which was then incubated at 35°C. At various times
after mixing (0, 30, 60, 90, and 120 min), 25-µl samples were
removed, diluted with 1 ml of ice-cold wash buffer (20 mM Tris [pH
7.5], 5 mM MgCl2, 1 mM DTT), and then filtered through
prewetted nitrocellulose membranes. The membranes were washed with 5 ml
of ice-cold wash buffer and then dried under a heat lamp. The amount of
unhydrolyzed, radioactive GTP remaining bound to the protein was
determined by liquid scintillation counting as previously described
(49).
GDP release assay for YPT1 proteins. Wild-type and mutant His-tagged YPT1 proteins (100 pmol) were incubated in 200 µl of buffer B (50 mM Tris-HCl [pH 7.5], 2.5 mM EDTA, 1 mM DTT, 20 mM KCl, 500 mg of BSA per ml, 1 mM ZnCl2) containing 5 nM [3H]GDP (10 mCi/mmol) for 15 min at 30°C. After incubation, MgCl2 was added to a final concentration of 5 mM, and the mixture was placed on ice for 10 min to allow nucleotide binding. Each [3H]GDP-labeled YPT1 protein was incubated at room temperature with 100 pmol of immobilized MBP-DSS4 or MBP as a control in reaction buffer (50 mM Tris-HCl [pH 7.5], 1 mM DTT, 20 mM KCl, 500 mg of BSA per ml, 1 mM ZnCl2, 100 mM GTP). At 0 and 60 min, 50 µl of the reaction mixture was removed and [3H]GDP binding was measured by a filter-binding assay and liquid scintillation counting.
Other materials and methods. Yeast transformations were performed by the lithium acetate method (31), and E. coli transformations were performed by electroporation as described by the Gene Pulser manufacturer (Bio-Rad) or by the CaCl2 method (65). E. coli strains were grown in Luria-Bertani medium (65) containing 100 µg of ampicillin per ml. Yeast strains were grown in yeast extract-peptone-dextrose medium or SC medium (72).
| |
RESULTS |
|---|
|
|
|---|
Yeast genetic analysis of GTPases binding to endogenous GEFs. Previously we exploited a yeast genetic system to identify amino acid residues in the switch II region of Ras which interact with GEFs (49). The rationale for this genetic system is based on the mechanism by which dominant interfering mutants of Ras cause growth arrest in yeast, that is, by binding to and sequestering essential GEFs (14, 20, 34, 58, 67). Thus, mutations in dominant interfering Ras which disrupt its interaction with GEFs are expected to suppress the dominant interfering lethal phenotype. However, mutations which cause global structural change are expected to suppress the dominant interfering phenotype without yielding information relevant to the protein-protein interaction sites. For this reason, the yeast genetic system that we used revealed intragenic suppressor mutants which were defective in GEF interactions without affecting other essential functions of Ras.
Segal et al. (68, 69) demonstrated that in addition to the switch II region of Ras, residues 103 and 105 in the
3-L7 region are
similarly involved in binding GEFs, in agreement with the crystal
structure of the H-ras-Sos complex (5). If the yeast
genetic system that we developed does indeed accurately identify
GEF-binding residues, we predicted that mutations in the
3-L7 region
would suppress the lethal phenotype of the dominant interfering
H-ras-N17 mutant. Further, we predicted that the
3-L7 mutations introduced into H-ras-V12 would not affect the ability of
activated Ras to suppress the loss of Ras function in yeast. We found
that the
3-L7 mutations (at residues 103 and 105) were intragenic
suppressors of the dominant interfering H-ras-N17 mutant (data not
shown). Further, when the
3-L7 mutations were introduced into
H-ras-V12, these mutations did not prevent suppression of the loss of
Ras function in yeast (data not shown).
Can a yeast genetic system be developed to identify amino acid residues in YPT1 which interact with GEFs? A yeast genetic system for identifying amino acid residues in YPT1 which interact with GEFs would have three general requirements. First, the system would require a dominant interfering mutant of YPT1 which induces a lethal phenotype. Second, the mechanism underlying the dominant interfering lethal phenotype would need to involve sequestering of GEFs. Third, a constitutively active YPT1 mutation, analogous to the H-ras-V12 mutation, would be needed in order to test the suppression of the loss of YPT1 function independent of endogenous GEF activity.
The dominant interfering H-ras-N17 mutation has been well characterized and is known to act through sequestering of essential GEFs (14, 20, 34, 67). We created the analogous YPT1-N22 mutant and determined whether it could induce a YPT1-null (lethal) phenotype in yeast. As shown in Fig. 1A, YPT1-N22, but not wild-type YPT1, induced a lethal phenotype when overexpressed under the control of the GAL1 promoter.
|
|
Intragenic suppressors of YPT1-N22.
Using the genetic system
described above, we sought mutations which disrupt the interaction of
YPT1 with endogenous yeast GEFs but do not interfere with the ability
of YPT1 to activate downstream targets. As a first step, we identified
intragenic suppressors of the dominant interfering YPT1-N22 mutation.
We predicted that Ras and YPT1 might interact with their cognate GEFs
by using analogous domains (see Discussion). The three regions of YPT1
that we thought might interact with GEFs are those corresponding to Ras
residues 30 to 42, 62 to 73, and 99 to 109. Therefore, we created in
the dominant interfering YPT1-N22 mutant a series of site-directed
mutations in the regions encompassing these residues. In addition, we
generated a pool of random mutations by hydroxylamine treatment of a
yeast expression vector containing YPT1-N22 under the control of the
GAL1 promoter. Among the site-directed and random mutations
obtained, we identified 17 intragenic suppressors of the lethal
phenotype of the dominant interfering YPT1-N22 mutant that did not
contain premature stop codons (Table 1).
Eleven of these mutations involved residues of YPT1 in regions
corresponding to the switch I (positions 42, 43, and 49), switch II
(positions 69, 71, 73, and 75), and
3-L7 (positions 107, 109, and
115) regions of Ras.
|
Intragenic suppressor mutations which do not interfere with downstream signaling. We next examined whether the intragenic suppressor mutations when combined with the YPT1-V17 mutation would retain the ability to interact with downstream targets and suppress the loss of YPT1 function in yeast. Four of the intragenic suppressor mutations (E42, K42, M43, and I49) that we identified are located in the effector loop region of YPT1; thus, because these mutations were unlikely to be able to interact with downstream targets, they were not tested in these experiments. However, in the discussion below, we argue that residues in the YPT1 effector loop region are involved in binding GEFs, consistent with the reports of Burstein and Macara (8) and Burton et al. (11).
Nine of the 13 intragenic suppressor mutations that we tested did not affect the ability of YPT1-V17 to interact with downstream targets, as judged by suppression of the ypt1-A136D mutation (Table 1 and Fig. 3A). Among these nine mutations, seven affected residues at positions 69, 71, 73, 75, 107, 109, and 115, which correspond to surface residues in the crystal structure of Ras (see Fig. 7). Four of these mutations (C69, C71, T73, and L75) are located in a region corresponding to the switch II region of Ras (residues 62 to 76), and three of them (A107, D109, and R115) are located in a region corresponding to the
3-L7 region of Ras
(residues 101 to 109). These seven altered residues are located in
regions of YPT1 analogous to the regions of Ras which are believed to be involved in binding GEFs. The other two intragenic suppressor mutations which did not affect the ability of YPT1-V17 to interact with
downstream targets (N89 and L95) correspond to H-ras-GTP residues
partially exposed and lying beneath residues 11, 12, and 13 of H-ras,
which Boriack-Sjodin et al. recently reported to interact with Sos1
(5). Thus, residues at these positions of YPT1 are probably
not directly involved in binding GEFs. However, we cannot rule out the
possibility that residues 89 and 95 of YPT1 become exposed by
interaction with GEFs.
|
In vitro interaction of DSS4 with YPT1 proteins with mutations in
the switch I, switch II, or
3-L7 region.
We examined the
ability of GST-YPT1 proteins with mutations in the region corresponding
to switch I (positions 42 and 49) and His-YPT1 proteins with mutations
in the switch II region (positions 68, 69, 71, 73, and 75) or the
3-L7 region (positions 107, 109, and 115) to bind MPB-DSS4 protein
in vitro in the absence of guanine nucleotides. Under conditions where
the wild-type GST-YPT1 protein, wild-type His-YPT1 protein, and mutant
His-YPT1-K68 protein (YPT1-K68 is not an intragenic suppressor of
dominant interfering YPT1-N22) were capable of binding MBP-DSS4,
GST-YPT1 or His-YPT1 mutant proteins with mutations at residues 42, 49, 69, 71, 73, 75, 107, 109, and 115 bound MBP-DSS4 significantly less
well (Fig. 4).
|
3-L7 region (Fig.
5). We first characterized the ability of
MBP-DSS4 to stimulate the release of [3H]GDP from
wild-type His-YPT1 in the presence or absence of excess unlabeled GTP.
Consistent with previous reports, DSS4 could stimulate the release of
[3H]GDP from YPT1 in the presence of excess guanine
nucleotide (9, 50) but not in its absence (data not shown).
Because an excess of guanine nucleotide is necessary, this finding
suggests that after DSS4 stimulates the release of
[3H]GDP from YPT1, a guanine nucleotide (provided here by
excess GTP) must bind to a DSS4-apo-YPT1 reaction intermediate before DSS4 can dissociate from YPT1 and thereby act (in a catalytic fashion)
on additional YPT1-[3H]GDP molecules.
|
3-L7 region in the presence of excess GTP. In these experiments, 35 to 40% of [3H]GDP dissociated from the His-YPT1 proteins
in the presence of MBP, reflecting the intrinsic loss of bound guanine
nucleotide that was not significantly affected by the mutations studied
here. In the presence of MBP-DSS4, 80% of the bound
[3H]GDP dissociated from wild-type YPT1. MBP-DSS4 failed
to dissociate [3H]GDP from mutants of His-YPT1 to the
same extent as it did for wild-type His-YPT1. The I73, L75, A107, D109,
and R115 mutants of YPT1 were not significantly recognized as
substrates for MBP-DSS4. The YPT1-C69 and YPT1-C71 mutants were
recognized as substrates by MBP-DSS4, although the extent of stimulated
release of [3H]GDP was significantly less (about
one-half) than that observed with wild-type YPT1.
| |
DISCUSSION |
|---|
|
|
|---|
YPT1, like Ras, interacts with cellular GEFs by use of switch I,
switch II, and
3-L7 sequences.
Our genetic analysis of small
GTPases suggests that Ras and YPT1 interact with GEFs through analogous
domains (but not homologous in terms of primary sequences). Several
mutations altering residues corresponding to the Ras switch I, switch
II, and
3-L7 regions abolish the dominant interfering lethal
phenotype of the YPT1-N22 mutant (Table 1). This result suggests that
these mutations prevent YPT1-N22 from binding the endogenous yeast GEFs
required for normal YPT1 function. When the switch II and
3-L7
mutations were introduced into the GTPase-defective YPT1-V17
mutant, the double mutants retained the ability to suppress the loss of
YPT1 function in yeast (Table 1 and Fig. 3A). This result indicates
that these mutations do not prevent YPT1 from interacting with
downstream effector molecules. Mutations in the switch II and
3-L7
regions in the context of nucleotide-free YPT1 prevented interactions with DSS4 in vitro (Fig. 4). Also, mutations in these regions in the
context of YPT1-GDP significantly reduced the ability of DSS4 to
promote nucleotide exchange (Fig. 5). Two mutants, YPT1-C69 and
YPT1-C71, did not exhibit profound defects in recognition by DSS4 in
the GDP release assay but did exhibit profound defects in the formation
of a stable complex with DSS4 in the absence of guanine nucleotide in
an in vitro binding assay. Differences in the structural requirements
for DSS4 recognition of YPT1-GDP versus DSS4 binding to apo-YPT1 may
explain the differences between these assays. The corresponding region
of H-ras (residues 63 and 65) has been shown to be significantly
altered in nucleotide-free Ras-Sos structures versus Ras-GDP or Ras-GTP
structures (5).
3-L7 region suppressed the loss of YPT1 function in
yeast. In the absence of the V17 mutation, YPT1 mutations at positions
71, 73, 75, 107, and 109 failed to suppress the loss of YPT1 function,
suggesting a requirement for YPT1 to bind a GEF in order to be
activated (Table 1 and Fig. 3B). The GTPase-defective YPT1 mutants thus
appear to bypass this requirement. The YPT1-R115 mutant appears to
bypass this requirement for a cellular GEF. This result does not appear
to be due to an increased intrinsic exchange rate or a defect in GTPase
activity (Fig. 5 and data not shown). All of the in vitro assays were
done at room temperature due to the instability of YPT1-GDP and the lack of DSS4 activity at higher temperatures. Thus, we cannot rule out
the possibility that at 37°C the YPT1-R115 mutant exhibits a
temperature-sensitive defect that permits it to achieve a GTP-bound state in yeast. Together, the yeast genetic and biochemical analyses described here are consistent with the conclusion that YPT1 proteins with normal GTPase activity must interact with an essential GEF through
residues in the switch II and
3-L7 regions in order to become active
(GTP bound) (62).
Ras as a structural model for the interaction of small GTPases with GEFs. The Ras superfamily of small GTPases can be subdivided into five families: the Ras, Rho, Ran, Arf, and Rab/YPT1 families (4, 25). GTPases in each of these families share a conserved core structure which forms a GTP-binding pocket (6). The common structural motifs are reflected in the homologous sequences shared among the different families (6). For example, 44 of the first 178 residues of H-ras are conserved in all five families.
While the GTPases in the five different families have some common properties, each is capable of family-specific functions. The Ras effector loop comprising residues 30 to 45 is highly conserved within the Ras family, but the corresponding sequences in the Rho, Ran, and Rab families are different from those in the Ras family (Fig. 6). However, within each family the sequences corresponding to these effector loop residues are highly conserved, suggesting a common function for this region among members of the same family. These sequences within the Ras, Rho, Arf, Ran, and Rab families are known to interact with downstream targets (2, 9, 39, 78). Thus, each family is characterized by interactions with family-specific targets via family-specific sequences corresponding to the Ras effector loop. Thus, Ras has proven to be a good model for the interactions of other small GTPases with their targets.
|
3-L7 regions together form a GEF-binding domain (Fig.
7). The sequences in these three regions
are highly conserved within the Ras family but are clearly distinct
from corresponding sequences in other GTPase families (Fig. 6). As shown in Fig. 6, the Rho, Ran, and Rab families have unique consensus sequences corresponding to the Ras switch I region, switch II region,
and
3-L7 region. These family-specific sequences may provide GTPases
in each family the ability to interact with family-specific GEFs.
|
3-L7 regions of Ras (Fig. 7). Thus, among the 35 residues that distinguish Rab molecules from other GTPases, 29 correspond to a cluster of surface residues. The six remaining residues
are scattered over the surface of Ras and are not clustered in a single
domain, which might be expected for a GEF-binding domain. Further,
relative to the orientation of Ras shown in Fig. 7C and D, these six
residues are all found on the "back side" of the molecule.
Therefore, from this sequence alignment analysis, we are able to
identify only one large YPT1 surface region that possesses
YPT1-specific sequences. Importantly, this analysis identifies each of
the sequences found to be involved in binding GEFs.
Arf and Rac GTPases may interact with GEFs by use of switch I,
switch II, and
3-L7 regions.
Recently, Mossessova et al.
(48) reported that the Arf GTPase may interact with its GEF,
Arno, by use of regions of the polypeptide which correspond to those
used by Ras to bind GEFs. This suggestion was based on the ability of
Arno to protect these three regions of Arf from hydroxyl radical
cleavage. However, the possibility that the protection from cleavage by
Arno induced structural changes in Arf cannot be ruled out. The
observation that Ras, YPT1, and possibly Arf use analogous domains to
interact with their family-specific GEFs raises the interesting
possibility that all small GTPases use a similar approach to bind GEFs.
In further support of this suggestion, we recently found preliminary evidence that the Rac GTPases use switch I, switch II, and
3-L7 sequences to bind endogenous GEFs in vivo as well as the Vav GEF in
vitro (17). Point mutations introduced into each of these three domains in the dominant interfering Rac-N17 mutant abolished its
inhibitory phenotype in cells. Rac proteins with mutations in these
three regions failed to interact with the Vav GEF under conditions
where wild-type Rac binds to Vav (17).
The GEFs or GRFs for the Ras, Rab, Rho, and Arf families of GTPases have common properties. The release of guanine nucleotides bound to the Ras, YPT1/Rab, Arf, and Rac families of GTPases can be stimulated by GEFs or GRFs specific for each of these distinct families of GTPases. Based on their amino acid sequences, the CDC25-type GEFs for Ras, the DSS4-type and Sec2-type GEFs for Rab, the Sec7-type GEFs for Arf, and the Dbl-type GEFs for Rho appear structurally unrelated. However, these distinct GEFs or GRFs share a number of similar functional properties. First, the physiological role of these GEFs or GRFs is to convert a GDP-bound GTPase to a GTP-bound GTPase. Second, each of these GEFs or GRFs stimulates the release of bound guanine nucleotides from their respective GTPase substrates. The major contribution to the overall exchange reaction mediated by each of these GEFs or GRFs is stimulation of the release of a bound nucleotide rather than stimulation of the uptake of a new nucleotide. Third, each of these GEFs or GRFs binds preferentially to nucleotide-free GTPases. This binary protein complex is generally thought to reflect an enzymatic reaction intermediate. Some GEFs or GRFs may bind equally well to GDP-bound, GTP-bound, and epo-GTPases, but this fact may reflect the use of GEF molecules that have not been properly modified for full activity, as we have noted for the Vav GEF (26). Fourth, the ability of each of these GEFs or GRFs to catalytically stimulate the release of [3H]GDP from their respective substrates requires the presence of excess guanine nucleotides (GDP or GTP). We previously referred to this activity as guanine nucleotide exchange activity because of the requirement of a guanine nucleotide to replace (or "exchange with") the released [3H]GDP (7). Fifth, mutations in the Ras-related GTPases at positions corresponding to Ras residue 17 result in GTPases with dominant interfering properties (i.e., null phenotype of the GTPase), and the mode of dominant interference is thought to be sequesteration of cellular GEFs or GRFs. Sixth, as discussed below, each of these GEFs or GRFs recognizes similar structural elements on the surface of the GTPases.
The Ras, YPT1/Rab, Arf, and Rac families of GTPases each appear to interact with GEFs by use of similar structural domains, namely, the switch I, switch II, and
3-L7 regions. This proposal could have
important implications for the mechanism of GEF-mediated nucleotide
exchange on all small GTPases as well as implications for the use of
GTPases with mutations in the GEF interaction domains. The interaction
of distinct families of GEFs with a common set of structural elements
on the GTPases suggests that some aspects of GEF-mediated GDP or GTP
exchange are common to the various families of GTPases. For
example, what is learned concerning the mechanism of the Sos
GEF-stimulated exchange on Ras (5) is likely to be relevant
to the mechanism of GEF-mediated exchange on Rac, Rab, and Arf GTPases.
The intrinsic properties of most (if not all) of the GEFs for
Ras-related GTPases do not exhibit a strong directionality; i.e., they
convert GTPase-GDP to GTPase-GTP only modestly better than the reverse
reaction. As the physiological role of the GEFs is generally thought to
produce GTPase-GTP molecules (rather than GTPase-GDP molecules),
additional factors have been thought to affect the direction of the
GEF-mediated reaction in the cell. Each of the Ras-related GTPases is
proposed to interact with GEFs, GAPs, and target molecules through the
switch I (effector loop) region. Therefore, consistent with in vitro
biochemical analysis (27), the interaction of a downstream
target with a GTP-bound GTPase in vivo is expected to block the
interaction with GEFs. The ability of target molecules to block GEF
interactions with GTPase-GTP molecules would then prevent GEFs from
acting on GTP-bound, but not GDP-bound, GTPases. This activity would
contribute to the overall direction of the GEF-mediated reaction to
favor a GTP-bound state. Also, because the GTP concentration in the
cell almost always exceeds the GDP concentration by 10-fold or more, the GEF- or GRF-mediated reaction favors the formation of GTP-bound GTPase. There are two intrinsic properties of GEFs and GTPases which
could also affect the direction of the exchange reaction. First,
GDP-bound GTPases appear to be recognized by GEFs more readily than
GTP-bound GTPases (Fig. 1B) (26, 37, 51). Second, reaction
intermediates (apo-Ras2-CDC25) are more readily disrupted by GTP than
by GDP (37, 49). Most detailed analyses of GEF-mediated reactions have used fragments of the GEF molecule; consequently, possible regions of GEF molecules that might have contributed to the
directionality of the reaction may have been overlooked (47, 49,
69, 73).
The use of point mutants of GTPases is a widely used approach in the
signaling field. For example, Ras switch I mutations have been widely
used to assess the contribution of various Ras effectors to the
phenotypes induced by Ras (35, 63, 79). A caveat to the use
of switch I mutations of Ras in the study of Ras effectors is that
these mutations also affect interactions with GEFs. Thus, in theory,
the partial loss of Ras signaling by these mutations could be due in
part to a loss of interactions with Ras GEFs. GTPase effector mutations
are often used in the context of a second mutation that impairs the GTP
hydrolysis activity of the GTPase; this effect is often suggested to
render the GTPase active independent of GEF activity. This suggestion
may not be completely accurate. Although RAS2-V19 (GTPase defective)
can bypass the requirement of CDC25 for cell viability, it is still responsive to the yeast CDC25 GEF (7). Also, many GEFs have the potential to interact with signaling molecules other than GTPases.
Vav, a GEF for Rac GTPase, interacts with phosphoinositide 3-kinase,
Grb2, Crk, Shc, Xyzin, ZAP-70, and SLP-76, as well as other molecules
(15). Also, Ras GEFs possess both a Ras GEF domain and a Rac
GEF domain and thus activate both Ras signaling and Rac signaling
(53, 61, 80). If any of the signaling properties of
these GEF-interacting proteins requires an interaction with
GTPases, then these signals would likely be affected by GTPase switch I mutants, even though these signals are not generally considered to be mediated by effectors. For example, in the case of Ras
GRF1, a Rac effector mutant might not bind to the DH domain of the Ras
GRF1, and if a DH-Rac interaction affected the activity of the CDC25
domain for Ras, the phenotype of the Rac effector mutant could in
theory differ from wild-type Rac phenotypes (18, 21).
Interestingly, the activity of the Ras GEF domain of Ras GRF was shown
to be dependent on the activity of the DH domain (18, 21).
Not all mutations of residues involved in protein-protein interactions
will significantly reduce the affinities of the proteins involved. This
idea is well illustrated by the use of effector mutations of GTPases
which, while preventing interactions with some target molecules, permit
interactions with others. In this regard, not all mutations in the
GEF-binding domain on GTPases are expected to prevent interactions with
all the GEFs for a GTPase. For example, a mutation in Ras that prevents
interactions with the yeast SCD25 GEF may not affect interactions with
GEFs for yeast CDC25 or vertebrate Sos1, Sos2, or cdc25 or Ras GRF.
Thus, it should be possible to isolate mutations of GTPases which
selectively prevent interactions with a subset of the GEFs for a
GTPase. Just as the use of effector mutations of GTPases has proven
useful for defining the signals downstream of GTPases, the use of GEF interaction site mutations in the switch II or
3-L7 regions of GTPases should prove useful in defining the contributions of various GEFs to the activation of GTPases.
The Ras, Rab, and Rho families of GTPases have been shown to be
regulated by GEFs which do not activate all members of the families.
The specificity of GEFs for some but not all GTPases in a family could
reflect structural differences in the GEF-binding domains of the
GTPases. As the emerging view of GEF-binding domains on GTPases has
defined the switch I, switch II, and
3-L7 regions, sequence
differences in these regions between different GTPases in the same
family could underlie the specificity of GEFs. As indicated in Fig. 6,
consensus sequences are present in the families of GTPases. However,
there are sequence differences among the members of the families of
GTPases. These sequence differences are likely to be involved in the
observed specificity of GEFs. For example, we have begun a mutational
analysis of the switch I, switch II, and
3-L7 regions which
distinguish the Rho, CDC42, and Rac GTPases (17). This
analysis could identify differences in Rho, CDC42, and Rac which
determine specific recognition by lbc, FGD1, and the DH domain of Sos1,
respectively (80).
| |
ACKNOWLEDGMENTS |
|---|
We are grateful to Sarah Jones, Nava Segev, and Peter Novick for providing reagents critical to these studies. We thank Sarah Jones for helpful discussion during the course of these studies.
This work was supported by NCI grant CA50261.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: 1441 Eastlake Ave., NOR-524, Los Angeles, CA 90033-0800. Phone: (323) 865-0523. Fax: (323) 865-0105. E-mail: broek{at}zygote.hsc.usc.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Ballester, R., T. Michaeli, K. Ferguson, H.-P. Xu, F. McCormick, and M. Wigler. 1989. Genetic analysis of mammalian GAP expressed in yeast. Cell 59:681-686[Medline]. |
| 2. | Becker, J., T. J. Tan, H.-H. Trepte, and D. Gallwitz. 1991. Mutational analysis of the putative effector domain of the GTP-binding YPT1 protein in yeast suggests specific regulation by a novel GAP activity. EMBO J. 10:785-792[Medline]. |
| 3. | Boguski, M. S., and F. McCormick. 1993. Proteins regulating Ras and its relatives. Nature 366:643-654[Medline]. |
| 4. | Bokoch, G. M., and C. J. Der. 1993. Emerging concepts in the Ras superfamily of GTP-binding proteins. FASEB J. 7:750-759[Abstract]. |
| 5. | Boriack-Sjodin, P. A., M. Margarit, D. Bar-Sagi, and J. Kuriyan. 1998. The structural basis of the activation of Ras by Sos. Nature (London) 394:337-343[Medline]. |
| 6. | Bourne, H. R., D. A. Sanders, and F. McCormick. 1991. The GTPase superfamily: conserved structure and molecular mechanism. Nature 349:117-127[Medline]. |
| 7. | Broek, D., T. Toda, T. Michaili, L. Levin, C. Birchmeier, M. Zollar, S. Powers, and M. Wigler. 1987. The S. cerevisiae CDC25 gene product regulates the RAS/adenylate cyclase pathway. Cell 48:789-799[Medline]. |
| 8. |
Burstein, E. S., and I. G. Macara.
1992.
Characterization of a guanine nucleotide-releasing factor and a GTPase-activating protein that are specific for the ras-related protein p25rab3A.
Proc. Natl. Acad. Sci. USA
89:1154-1158 |
| 9. |
Burstein, E. S.,
W. H. Brondyk, and I. G. Macara.
1992.
Amino acid residues in the ras-like GTPase Rab3A that specify sensitivity to factors that regulate the GTP/GDP cycling of Rab3A.
J. Biol. Chem.
267:22715-22718 |
| 10. | Burton, J. L., D. Roberts, M. Montaldi, P. Novick, and P. DeCamilli. 1993. A mammalian guanine nucleotide releasing protein enhances function of yeast secretory protein Sec4. Nature 361:464-467[Medline]. |
| 11. |
Burton, J. L.,
V. Slepnev, and P. V. De Camilli.
1997.
An evolutionarily conserved domain in a subfamily of Rabs is crucial for the interaction with the guanyl nucleotide exchange factor Mss4.
J. Biol. Chem.
272:3663-3668 |
| 12. | Chardin, D. 1993. Structural conservation of ras-related proteins and its functional implications, p. 159-176. In F. D. Burton, and B. Lutz (ed.), GTPases in biology I, vol. 108. Spring-Verlag KG, Berlin, Germany. |
| 13. |
Chen, J.,
R. Lansford,
V. Stewart,
F. Young, and F. W. Alt.
1993.
RAG-2-deficient blastocyst complementation: an assay of gene function in lymphocyte development.
Proc. Natl. Acad. Sci. USA
90:4528-4532 |
| 14. | Chen, S. Y., S. Y. Huff, C. C. Lai, C. J. Der, and S. Powers. 1994. Ras-15A protein shares highly similar dominant-negative biological properties with Ras-17N and forms a stable, guanine-nucleotide resistant complex with CDC25 exchange factor. Oncogene 9:2691-2698[Medline]. |
| 15. | Collins, T. L., M. Deckert, and A. Altman. 1997. Views on Vav. Immunol. Today 18:221-225[Medline]. |
| 16. |
Crechet, J.-B.,
A. Bernardi, and A. Parmeggiani.
1996.
Distal switch II region of Ras2p is required for interaction with guanine nucleotide exchange factor.
J. Biol. Chem.
271:17234-17240 |
| 17. | Day, G.-J., and D. Broek. Unpublished results. |
| 18. | Fan, W.-T., A. Koch, C. L. de Hoog, N. P. Fam, and M. F. Moran. 1998. The exchange factor Ras-GRF2 activates Ras-dependent and Rac-dependent mitogen-activated protein kinase pathways. Curr. Biol. 8:935-938[Medline]. |
| 19. | Feig, L. A. 1994. Guanine-nucleotide exchange factors: a family of positive regulators of Ras and related GTPases. Curr. Opin. Cell Biol. 6:204-211[Medline]. |
| 20. |
Feig, L. A., and G. M. Cooper.
1988.
Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP.
Mol. Cell. Biol.
8:3235-3243 |
| 21. | Freshney, N. W., S. D. Goonesekera, and L. A. Feig. 1997. Activation of the exchange factor Ras-GRF by calcium requires an intact Dbl homology domain. FEBS Lett. 407:111-115[Medline]. |
| 22. | Gallwitz, D., C. Donath, and C. Sander. 1983. A yeast gene encoding a protein homologous to the human c-has/bas proto-oncogene product. Nature (London) 306:704-707[Medline]. |
| 23. |
Gibbs, J. B., and M. S. Marshall.
1989.
The ras oncogene an important regulatory element in lower eucaryotic organisms.
Microbiol. Rev.
53:171-185 |
| 24. | Goldberg, J. 1998. Personal communication. |
| 25. | Hall, A. 1993. Ras-related proteins. Curr. Opin. Cell Biol. 5:265-268[Medline]. |
| 26. | Han, J., B. Das, W. Wei, L. Van Aelst, R. D. Mosteller, R. Khosravi-Far, J. K. Westwick, C. J. Der, and D. Broek. 1997. Lck regulates Vav activation of members of the Rho family of GTPases. Mol. Cell. Biol. 17:1346-1353[Abstract]. |
| 27. | Han, J., and D. Broek. 1998. Personal communication. |
| 28. |
Haney, S. A., and J. R. Broach.
1994.
Cdc25p, the guanine nucleotide exchange factor for the Ras proteins of Saccharomyces cerevisiae, promotes exchange by stabilizing Ras in a nucleotide-free state.
J. Biol. Chem.
269:16541-16548 |
| 29. | Haubruck, H., C. Disela, P. Wagner, and D. Gallwitz. 1987. The ras-related ypt protein is an ubiquitous eukaryotic protein: isolation and sequence analysis of mouse DNA highly homologous to the yeast YPT1 gene. EMBO J. 6:4049-4053[Medline]. |
| 30. | Horiuchi, H., R. Lippe, H. M. McBride, M. Rubino, P. Woodman, H. Stenmark, V. Rybin, M. Wilm, K. Ashman, M. Mann, and M. Zerial. 1997. A novel Rab5 GDP/GTP exchange factor complexed to Rabaptin-5 links nucleotide exchange to effector recruitment and function. Cell 90:1149-1159[Medline]. |
| 31. |
Ito, H.,
Y. Fukuda,
K. Murata, and A. Kimura.
1983.
Transformation of intact yeast cells treated with alkali cations.
J. Bacteriol.
153:163-168 |
| 32. |
Jedd, G.,
C. Richardson,
R. Litt, and N. Segev.
1995.
The YPT1 GTPase is essential for the first two steps of the yeast secretory pathway.
J. Cell Biol.
131:583-590 |
| 33. |
Jones, S.,
R. J. Litt,
C. J. Richardson, and N. Segev.
1995.
Requirement of nucleotide exchange factor for Ypt1 GTPase mediated protein transport.
J. Cell Biol.
130:1051-1061 |
| 34. |
Jung, V.,
W. Wei,
R. Ballester,
J. Camonis,
S. Mi,
L. Van Aelst,
M. Wigler, and D. Broek.
1994.
Two types of RAS mutants that dominantly interfere with activators of RAS.
Mol. Cell. Biol.
14:3707-3718 |